Mr. Murphy co-founded Organovo in 2007 and has led all company operations since that time. He co-invented the company’s NovoGen MMX bioprinter platform and grew the company through early investments and corporate partnerships. Since going public in 2012, the company has focused on the development of three-dimensional liver, kidney, and cancer tissues. The most advanced program, liver tissue, has grown to encompass a range of applications from commercial use for pharmaceutical toxicology prediction to the preclinical development of human 3D liver patches for transplant patients. Prior to co-founding Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($3B+ annual sales). He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. He currently serves on the Board of the California Life Sciences Association.